Bisi, John E.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 770

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 255

Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression

Roberts, P. J., White, H. S., Sorrentino, J. A., Tadema, H., Sale, M., Tiessen, R. G., Bisi, J. E., Makhuli, K. M., Hoogdalem, E.-J. V., Malik, R. K., et al. (2015) · Journal of Clinical Oncology

Hematopoietic Stem Cell TransplantationNeutropenia and Cancer Infections

Cited by 3